- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05992298
Feasibility Testing of 7-Tesla Magnetic Resonance Imaging
August 7, 2023 updated by: Reto Sutter, MD
Explorative Technical Feasibility Testing of 7-Tesla Magnetic Resonance Imaging of the Musculoskeletal System and of the Head
The goal of the current project is to explore and develop the technical feasibility of non-invasive imaging of the human musculoskeletal system and head with the first 7T MR scanner with a CE mark to identify areas where the higher field promises significant benefits in qualitative image quality.
For a subset of the planned exams, state-of-the art 7T or 3T images will be used as standard of reference to comparatively gauge the qualitative image quality of the investigational 7T images.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
780
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Reto Sutter, Prof.
- Phone Number: +41 44 386 33 08
- Email: reto.sutter@balgrist.ch
Study Contact Backup
- Name: Daniel Nanz, Prof.
- Phone Number: +41 44 510 70 04
- Email: daniel.nanz@balgristcampus.ch
Study Locations
-
-
-
Zurich, Switzerland, 8008
- Recruiting
- Balgrist University Hospital
-
Contact:
- Reto Sutter, Prof.
- Phone Number: +41 44 386 33 08
- Email: reto.sutter@balgrist.ch
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Consent to undergo a 7T (and, if appropriate a comparative 3T) MRI exam.
- For some of the consistent small series: presence of a specific condition of the musculoskeletal system or of the head. This can include traumatic or degenerative changes, e.g., of tendons, cartilage, muscle, peripheral nerves, ligaments, and bones, or in the brain, as well as focal lesions, e.g., tumors.
Exclusion Criteria:
- Contraindications to undergo a MRI examination at a field strength of 7 Tesla or at 3 Tesla.
- Irregular anatomy and/or tissue properties
- Inability to consent - for any reason.
- Body mass above 200 kg.
- Body mass below 30 kg.
- Women: pregnancy.
- Age below 18.
- Known or suspected non-compliance, drug or alcohol abuse.
- Inability to follow the procedures of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 7 T MRI
|
Adult healthy and patient volunteers will undergo a ca. 1 hour examination of non-invasive magnetic-resonance imaging at 7T, and, if appropriate, a closely matching examination at 3T as a standard of reference.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Qualitative image quality of 7 T MRI
Time Frame: through study completion, an average of 1 year
|
Current-day feasibility of various types of MR examinations of the human musculoskeletal system.
The primary outcomes of small consistent series of the study are visual gradings and qualitative measures of image quality.
Image quality is rated by independent readers using Likert scales.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Reto Sutter, Prof., Balgrist University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 7, 2023
Primary Completion (Estimated)
February 29, 2024
Study Completion (Estimated)
February 29, 2024
Study Registration Dates
First Submitted
July 18, 2023
First Submitted That Met QC Criteria
August 7, 2023
First Posted (Actual)
August 15, 2023
Study Record Updates
Last Update Posted (Actual)
August 15, 2023
Last Update Submitted That Met QC Criteria
August 7, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- I0171
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Magnetic Resonance Imaging
-
BayerCompletedMagnetic Resonance Imaging | Magnetic Resonance AngiographyPoland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
-
Centre Hospitalier Régional Metz-ThionvilleUniversity of LorraineRecruitingMagnetic Resonance ImagingFrance
-
Jessa HospitalActive, not recruitingMagnetic Resonance ImagingBelgium
-
BayerCompletedMagnetic Resonance ImagingUnited States, Korea, Republic of, France, Germany, Italy, Switzerland, United Kingdom
-
Boston Scientific CorporationCompletedMagnetic Resonance ImagingSpain, Hong Kong, Germany, Israel, United Kingdom, Italy, United States, Malaysia, Belgium
-
Centre Hospitalier Universitaire, AmiensCompletedMagnetic Resonance ImagingFrance
-
MegaPro Biomedical Co. Ltd.CompletedMagnetic Resonance ImagingTaiwan
-
BayerCompletedMagnetic Resonance ImagingJapan
-
BayerCompletedMagnetic Resonance ImagingPhilippines
-
BayerCompletedMagnetic Resonance Imaging | Myocardial Perfusion ImagingSwitzerland, Germany, Austria, Poland
Clinical Trials on 7 T MRI vs 3 T MRI
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Maastricht Radiation OncologyThe Limburg University FundTerminated
-
Nottingham University Hospitals NHS TrustJohns Hopkins UniversityNot yet recruitingMultiple Sclerosis
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingHypogonadism | Malignant Testicular Germ Cell TumorUnited States
-
Radboud University Medical CenterUnknown
-
NYU Langone HealthWithdrawnBreast Cancer | BRCA1 Mutation | BRCA2 MutationUnited States
-
GE HealthcareWellcome TrustTerminatedImage EvaluationUnited States
-
University Hospital Inselspital, BerneRecruitingCerebral Small Vessel Diseases | Intracerebral Hemorrhage | CAA - Cerebral Amyloid AngiopathySwitzerland
-
University of Texas Southwestern Medical CenterCancer Prevention Research Institute of TexasCompletedMalignant Gliomas | Astrocytomas | OligodendrogliomasUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingMetastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the BrainUnited States